Global /Sweden /Healthcare /Drug Manufacturers - General /NICA

Nanologica AB (publ)

NICA

• STO: NICA • Delayed

0.5300SEK 1.5%

0.0554 USD

As of 24 June 2026, Nanologica AB (publ) has a market cap of $6.51M USD, ranking #43417 globally and #697 in Sweden. It ranks #3845 in the Healthcare sector, and #1242 in the Drug Manufacturers - General industry.

Global Rank

43417

Country Rank

697

Sector Rank

3845

Industry Rank

1242

Key Stats

Market Cap

$6.51MUSD

62.63M SEK

Enterprise Value

$11.4MUSD

109.13M SEK

Revenue (TTM)

$2.2MUSD

21.13M SEK

EBITDA (TTM)

-$3.59MUSD

-34.37M SEK

Net Income (TTM)

-$5.33MUSD

-51.29M SEK

EBITDA Margin

-163%

Profit Margin

-243%

PS Ratio

3.0

PB Ratio

2.8

Company Profile

Country (HQ)

Sweden

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Andreas Bhagwani open_in_new

Employees

Founded

2004

Website

nanologica.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
1.5%	-51%	49%	-13%	-60%	-33%	-50%	-94%	-97%

News

Markets

Exchange	Ticker	Price	Quotes
Nasdaq Stockholm (STO) MIC: XSTO PRIMARY	NICA Nanologica AB ISIN: SE0005454873 Shares Out.: Shares Outstanding: 328.77M¹ Shares Float: 200.331M² TV: TradingView: OMXSTO: NICA SA: Stock Analysis: STO: NICA YF: Yahoo Finance: NICA.ST GF: Google Finance: STO: NICA BA: Barron's: NICA MS: Morningstar: XSTO: NICA	0.5300 SEK	TV: TradingView: OMXSTO: NICA SA: Stock Analysis: STO: NICA YF: Yahoo Finance: NICA.ST GF: Google Finance: STO: NICA BA: Barron's: NICA MS: Morningstar: XSTO: NICA

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Nanologica AB (publ)

Nanologica AB (publ), a nanotechnology company, develops, manufactures, and sells nanoporous silica particles for life science industry in China, India, the United State of America, and internationally. It offers NLAB Saga, a new generation silica for preparative chromatography; and SVEA, a pre-packaged columns for analytical chromatography; and high-performance liquid chromatography, a separation method based on different substances in a solution passing through a column at different paces. The company provides products for the analysis and purification of substances, with a focus on peptides drugs for the treatment of diabetes and obesity. Nanologica AB (publ) was incorporated in 2004 and is headquartered in Södertälje, Sweden.

Similar Companies

Industry: Drug Manufacturers - General (Sweden)

Name	Market Cap (USD) diff.	PE	Country
Swedish Orphan Biovitrum AB (publ) STO: SOBI	$14.49B 139.44B SEK 223K%	152.8	Sweden
Camurus AB (publ) STO: CAMX	$3.26B 31.37B SEK 50K%	42.8	Sweden
BioArctic AB (publ) STO: BIOA-B	$2.86B 27.5B SEK 44K%	26.9	Sweden
Swedencare AB (publ) STO: SECARE	$440.25M 4.24B SEK 7K%	85.9	Sweden
Vicore Pharma Holding AB (publ) STO: VICO	$293.19M 2.82B SEK 4K%	-	Sweden
Hansa Biopharma AB (publ) STO: HNSA	$286.42M 2.76B SEK 4K%	-	Sweden

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 12M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 8M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 6M%	97.4	United States
Roche Holding AG SIX: RO	$316.71B 256.25B CHF 5M%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$285.49B 215.59B GBP 4M%	27.6	United Kingdom
Merck & Co., Inc. NYSE: MRK	$274.03B 4M%	15.1	United States

chevron_leftBack